Treating genetic blood disorders in the era of CRISPR-mediated genome editing
Open Access
- 18 January 2025
- journal article
- review article
- Published by Elsevier in Molecular Therapy
- Vol. 33 (6) , 2645-2662
Abstract
No abstract availableKeywords
Funding Information
- Shaqra University
- Cardiff University
- Saudi Arabian Cultural Bureau
This publication has 157 references indexed in Scilit:
- Examining Mental Health, Education, Employment, and Pain in Sickle Cell DiseaseJAMA Network Open, 2023
- Sickle Cell DiseaseJAMA, 2022
- Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome EditingChemBioChem, 2021
- Improving Gene Editing Outcomes in Human Hematopoietic Stem and Progenitor Cells by Temporal Control of DNA RepairStem Cells, 2018
- A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell DiseaseStem Cells Translational Medicine, 2017
- Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical fieldScience China Life Sciences, 2017
- Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital usePediatric Blood & Cancer, 2016
- CRISPR‐Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategiesInternational Journal of Cancer, 2015
- PEG conjugation moderately protects adeno‐associated viral vectors against antibody neutralizationBiotechnology and Bioengineering, 2005
- Intervening Sequences of Regularly Spaced Prokaryotic Repeats Derive from Foreign Genetic ElementsJournal of Molecular Evolution, 2005